Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 8, 2013, Pages 4847-4851

  Uzel, Esengul Kocak ^a   Ekmekcioglu, Ozgul ^b   Elicin, Olgun ^b   Halac, Metin ^b   Uzel, Omer Erol ^b  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Head and neck cancer; Nasopharyngeal cancer; PET CT; Response evaluation; SUV

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84885760698     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.8.4847     Document Type: Article

References (28)

1. Andrade RS, Heron DE, Degirmenci B, et al (2006). Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys, 65, 1315-22.
2. Bastiaannet E, Groen H, Jager PL, et al (2004). The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: A systematic review and meta-analysis. Cancer Treat Rev, 30, 83-101.
3. De Santis M, Becherer A, Bokemeyer C, et al (2004). 2-[18]Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol, 22, 1034-9.
4. Ding M, Newman F, Raben D (2005). New radiation therapy techniques for the treatment of head and neck cancer. Otolaryngol Clin North Am, 38, 371-95.
5. Eisbruch A, Marsh LH, Dawson LA, et al (2004). Recurrences near base of skull after IMRT for head-and-neck cancer: Implica-tions for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys, 59, 28-42.
6. El-Sayed S, Nelson N (1996). Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and random-ized trials. J Clin Oncol, 14, 838-47.
7. Hain SF, O'Doherty MJ, Timothy AR, et al (2000). Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med, 27, 590-4.
8. HigginsKA, Hoang JK, Roach MC, et al (2012). Analysis of Pretreatment FDG-PET SUV parameters in Head-and-Neck Cancer: Tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys, 82, 548-53.
9. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Statist Assoc, 53, 457-81.
10. Lee N, Xia P, Fischbein NJ, (2003). Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys, 57, 49-60.
11. Lefebvre JL, Chevalier D, Luboinski B, et al (1996). Larynx preservation in pyriform sinus cancer: Preliminary results of a Eu-ropean Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst, 88, 890-9.
12. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep, 5, 163-70.
13. Moeller BJ, Rana V, Cannon BA, et al (2009). Prospective risk-adjuste [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol, 20, 2509-15.
14. Murphy JD, La TH, Chu K, et al (2011). Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 80, 514-21.
15. Paccagnella A, Orlando A, Marchiori C, et al (1994). Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst, 86, 265-72.
16. Paola Castaldi,Vittoria Rufini,Francesco Bussu, et al (2012). Can early and late 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol, 3, 63-8.
17. Passero VA, Branstetter BF, Shuai Y, et al (2010). Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol, 21, 2278-83.
18. Pfister DG, Shaha AR, Harrison LB (1997). The role of chemotherapy in the curative treatment of head and neck cancer. Surg Oncol Clin N Am, 6, 749-68.
19. Pignon JP, le Maitre A, Maillard E, Bourhis J, (2009). Meta-analysis of chemo-therapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17, 346 patients. Radiother Oncol, 92, 4-14.
20. Prestwich RJ, Subesinghe M, Gilbert A, et al (2012). Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Clin Radiol, 67, 966-75.
21. Rose PG, Adler LP, Rodriguez M, et al (1999). Positron emission tomography for evaluating paraaortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study. J Clin Oncol, 17, 41-5.
22. Scarfone C, Lavely WC, Cmelak AJ, et al (2004). Prospective feasibil-ity trial of radiotherapy target definition for head and neck can-cer using 3-dimensional PET and CT imaging. J Nucl Med, 45, 543-52.
23. Schwartz DL, Ford E, Rajendran J, et al (2005). FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 61, 129-36.
24. Trautmann TG, Zuger JH, (2005). Positron Emission Tomography for Pretreatment Staging and Posttreatment Evaluation in Cancer of the Anal Canal. Mol Imaging Biol, 7, 309-13.
25. Troost EG, Schinagl DA, Bussink J, Oyen WJ, Kaanders JH (2010). Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. Radiother Oncol, 96, 328-34.
26. Wong RJ, Lin DT, Schöder H et al (2002). Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma. J Clin Oncol, 20, 4199-208.
27. Yanagawa M, Tatsumi M, Miyata H, et al (2012). Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors. J Nucl Med, 53, 872-80.
28. Yao M, Smith RB, Graham MM, et al (2005). The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys, 63, 991-9.